Member Info for Ghia

USAIN and others intent on discussion TILS on this message board please can you respectfully move your conversation to the appropriate board please. Many people have portfolios that include a variety of investments and manage perfectly well to keep track of what board they are on.

Occasional discussions, out of market hours or at weekends do not cause as much irritation but repeated dialogue about a single share is frustrating and adds limited value to the research and discussion surrounding SNG.

Thank you in advance

Medicalstudent - I hope you will stick around really valuable contribution to the board with those two posts. Thanks.

Nice work on the £2.20 exit by the way it was painful holding these when it slid to the low 30's but you should have made a tidy profit for holding on.

DubD - I still have 70% of my original holding. I had the best made plans prior to news to sell 80% when my price target was met, but the results exceeded my expectations significantly so I adjusted accordingly.

I'm holding until Licensing/Takeover or material news that changes the course here.

Thanks BIG - I hoped it would be similar to a divi ref procedure.

Mrinjazx6 - Fair enough, time will tell if it was a slice or something more but my money is on them staying put for now.

busymumof3 - I'm here for Stem, I'm sure TILS has plenty of other interesting things in the pipeline but I'd rather get the stem shares and bank whatever profit may be left in TILS, might leave some free shares to run but I have too many other shares to research and keep on top of to add TILS to the list with everything it has going on.

What does the record date actually mean?

If I hold shares on or before the record date I qualify for the spin off shares, but do I have to continue to hold until the split is complete or can I ditch TILS after the record date?

If I'm honest I invested purely for the Stem split I expect TILS to drop a fair amount once the split has happened and the spin off shares are the ones that I'd like to keep hold of.

II’s are no longer suppressing this.

Quite the contrary the reason this has held it’s stellar 500% rise is the fact that II’s have bought in stabilising the price.

Lansdowne top slice and the share price barely moves fantastic sign.

New II’s on board that have paid £2+ even better sign.

It’s really good to see this trading a range and holding it’s gains.

Morningstar likely to update their data on Friday I expect to see a few new names on the list of II’s

The main play here is obviously inhaled IFN-B1A but some of the recent additions to the board may not be aware that we also own a 20% stake in Loxl-2.

http://www.pharmaxis.com.au/product-pipeline/amine-oxidase-platform/loxloxl2/

Colber - This was the official wording in the RNS on the AZN decision. Strategic decision despite positive effects.

"AZD9412 (SNG001) INEXAS clinical trial update, announcing AstraZeneca's decision to return the rights of inhaled interferon beta (IFN-beta) to Synairgen for strategic reasons, despite positive effects on markers of antiviral activity and lung function"

Rich - Just to clarify when you are talking about guaranteed stops this is with spreadbets? I've never seen option for a guaranteed stop loss on physical shares.

Colber - Well done for sticking it out with the slide from the 60's down to 31p lots of PI's would have realised significant losses during that period. Noticed you first posted in May.

Taverham - I personally think that they probably had deals already on the table pending trial results, hence applying for COPD interim access to support the hospital data.

The twist being they underestimated the significance of the hospital data and the spectacular results have given them leverage over majors to push up the price.

Once the regulators are satisfied with the data I think this will move quickly. COPD results first week of August would fit the time line.

All speculation of course.

Avoid stop losses like the plague they are not guaranteed and the price action on AIM can swing huge amounts in no time at all.

So many stories of investors having their stop loss triggered, shares selling for way below their stop price and then the share ending up blue for the day with them having to buy in higher.

Colber - Stick around you will always get a mixed bag of responses. Seems clear to me your intentions are genuine.

Just read the article you posted, there's not a lot of meat in there other than that they are patting themselves on the back for their previous recommendation to sell.

There are some important rules in investing some key ones for me:
1. Own your own research
2. Preserve your capital

I think most people will have taken a bit off the table after the 500% rise, I personally did. I did this because I've been burnt before and learned to protect my capital. If you can protect your capital you live to fight another day when things go sour.

If I solely listened to my research I would have kept it all in but I am human and concede I don't always get things right.

As for the article the reasons AZN walked away was that not enough Asthma patients where suffering exacerbations on the trial, so whilst the drug was doing the right things in terms of improving lung function, the target population was not getting sick enough so they had nothing to trial. They assumed the market was not there so walked away.

Fast forward to now and we have a deadly Virus infecting people globally of which Asthma and COPD patients are amongst the at Risk population. There is no question now that the market for this drug is massive I believe AZN decision would have been different had they foreseen this.

Whether you sell half or not is your decision and your decision alone.

DiscoDividends - I think it covers the formulation required to deliver IFN-Beta1A via nebulisation. So in broad terms nebulised delivery of IFN-Beta1A unless another company can figure out a unique formula that does the same thing (Hint: it took 15years for SNG to get to this point).

The patent also covers a broad spectrum of rhinoviruses, influenza type infections so it is broad in that respect too.

Manifesto - The potential scope for this drug is why 1billion+ valuations are potentially realistic.

The data will do the talking, I trust RM & Co know the value of what they have.

SNG have a patent on the nebulisation of IFN -beta 1a

It will be interesting to see the trial data for IFN-beta 1a via IV FARON are the company behind this.

Betterlife have Inhaled - IFN Alpha2b They are starting new trials soon.

It’s likely all of the above with show benefit the good news for us is that current data and studies point to IFN-beta 1 a being the most promising.

And inhalation straight to the lungs the optimum delivery method.